GERD treatment drug
Scope
Date
~
-
Bio & Pharma
HK inno.N's K-CAB to get insurance benefits in China
South Korea’s 30th novel medicine K-CAB Tab (active ingredient: tegoprazan), a gastroesophageal reflux disease (GERD) treatment of HK inno.N, ...
Jan 20, 2023 (Gmt+09:00)
-
Bio & Pharma
ST Pharm exports $14.6 mn worth of drug ingredients to Europe
ST Pharm Co., a South Korean company specializing in contract development and manufacturing of drug ingredients, has signed a supply contract worth ...
Jan 20, 2023 (Gmt+09:00)
-
Bio & Pharma
LG Chem completes acquisition of US biotech firm AVEO
LG Chem Ltd. is set to complete its $571 million purchase of the US biotech firm AVEO Pharmaceuticals Inc. on Friday, which would strengthen its ant...
Jan 19, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma's Sanfilippo treatment eligible for FDA priority review
GC Biopharma Corp. said on Wednesday that its Sanfilippo type A treatment, which is under joint development with Novel Pharma, a bio-venture special...
Jan 18, 2023 (Gmt+09:00)
-
Bio & Pharma
MedPacto's anti-cancer substance designated as US FDA fast-track item
South Korean biotech company MedPacto Inc. ’s Vactosertib monotherapy for osteosarcoma patients has been designated as a fast-track developmen...
Jan 18, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong accelerates investment in CDMO business
Daewoong, the holding company of South Korea's pharmaceutical-oriented Daewoong Group, is speeding up its pace to beef up its contract development a...
Jan 18, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma
Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...
Jan 16, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Chemicals launches uremia itching treatment tablet
SK Chemicals said on Monday that it has launched Remitch in orally disintegrating tablets, a treatment for intractable uremic pruritus (uremia itchi...
Jan 16, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N gets approval to sell K-CAB in Singapore
South Korean biohealth company HK inno.N said on Wednesday that it has received an item approval for K-CAB, a new drug for gastroesophageal reflux d...
Jan 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Prestige Biopharma attains patent for solid cancer treatment antibody
Prestige Biopharma Korea said on Tuesday that it has obtained a domestic patent for the CTHRC1 neutralizing antibody of the drug candidate PBP1710. ...
Jan 12, 2023 (Gmt+09:00)
-
Bio & Pharma
JVM to sell fully automated drug inspection machines in US
Hanmi Pharmaceutical Co. said on Monday that it had signed an agreement with Euclid Medical Products, a company specializing in manufacturing drug d...
Jan 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion develops oral antibody drug with US bio company
South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...
Jan 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Kolon signs MOU with Hanyang Univ. to develop gene therapy treatments
Kolon Industries Inc.'s Future Technology Institute said on Thursday that it had signed a memorandum of understanding with the Hanyang University In...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong, Onchorus to undertake research on mRNA anticancer drugs
Daewoong Pharmaceutical said on Thursday that it has signed a joint R&D and commercialization agreement with America's biopharmaceutical venture...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
NeoImmuneTech, US think tank to develop treatment for acute radiation syndrome
Biopharmaceutical company NeoImmuneTech has grabbed an opportunity to supply new drug candidates in development as strategic items to the US gover...
Jan 04, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Remsima receives approval in 100 countries in 10 years
South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...
Jan 03, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB confirms ophthalmic disease treatment in phase 3 clinical trials
South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effectiv...
Jan 03, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Chemicals introduces Tiglutik, treatment for Lou Gehrig's disease
SK Chemicals said on Monday that it is strengthening its portfolio of neurological diseases by introducing Tiglutik (riluzole), Lou Gehrig's disease...
Jan 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma, Neurolive to jointly develop new antidepressant drug
South Korea's drug company Daewoong Pharmaceutical said on Wednesday that it has signed an agreement with biopharmaceutical venture Neurorive to joi...
Dec 28, 2022 (Gmt+09:00)
-
Bio & Pharma
KOICA donates Celltrion's Herzuma to Ukraine
Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
CJ applies to FDA for trials of immuno-anticancer drug candidate
CJ Bioscience, an independent red bio (pharmaceutical and healthcare) subsidiary of CJ CheilJedang Corp., said on Monday it has submitted a phase 1 ...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
CENYX Biotech, developing treatment for brain damage with ROS-scavenging, nano-sized heavy metals
When severe brain diseases such as cerebral infarction or cerebral hemorrhage occur, the blood-brain barrier (BBB) in our body no longer functions p...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
LegoChem Bio, Amgen sign ADC platform deal for up to $1.2 bn
South Korean pharmaceutical firm LegoChem Biosciences Inc. said on Dec. 23 it has transferred the antibody-drug conjugates (ADC) technology platform...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
Dong-A ST incorporates NeuroBo as subsidiary
Dong-A ST said on Friday that it would acquire American drug company NeuroBo Pharmaceuticals as a subsidiary.NeuroBo, located in Boston, is a Nasdaq...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for FDA approval for Remsima SC
Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
ToolGen, ANLBIO to jointly develop progeria treatments
South Korea's two biotech startups ToolGen Incorporated and ANLBIO on Tuesday signed a joint research and development agreement for developing proge...
Dec 21, 2022 (Gmt+09:00)
-
Bio & Pharma
S.Korean biopharmaceutical sector to see brisk M&As in H1, 2023
An expert says the first half of next year will see the start of brisk M&As in biopharmaceuticals targeting strategic investors.Pyeon Jae-seong,...
Dec 21, 2022 (Gmt+09:00)
-
Artificial intelligence
Syntekabio launches new drug development platform STB Cloud in US
Syntekabio,Inc., a South Korean artificial intelligence (AI) drug development company, said on Monday it has launched its cloud-based AI drug develo...
Dec 19, 2022 (Gmt+09:00)
-
Bio & Pharma
JW Pharma applies for phase 3 trial in Taiwan for gout treatment
JW Pharmaceutical announced through its disclosure on Monday that it had applied last Friday for a phase 3 trial for Epaminurad, a gout treatment, w...
Dec 19, 2022 (Gmt+09:00)
-
Bio & Pharma
LG Chem in $95.5 million drug out-licensing deal with China’s Innovent
LG Chem Life Sciences, the biopharmaceutical unit of LG Chem Ltd., and China’s biotech company Innovent Biologics have entered into a strategi...
Dec 15, 2022 (Gmt+09:00)